Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:

NCT ID: NCT05540795 Completed - Clinical trials for Secondary Hyperparathyroidism

Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT

Start date: February 6, 2023
Phase:
Study type: Observational

Secondary hyperparathyroidism (SHPT) is a common serious complication in the maintenance process of hemodialysis patients, characterized by diffuse or nodular hyperplasia of parathyroid glands. Parathyroidectomy for patients with drug-refractory SHPT is recommended in the clinical practice guidelines of the Global Organization for Improving Prognosis in Kidney Disease (KDIGO) and the Japanese Dialysis Therapy Society (JSDT) . Therefore, accurate localization and detection of parathyroid abnormalities is the key to avoid persistent recurrence of the disease. However, the sensitivity and specificity of the existing ultrasound and 99MTC-MIBI diagnosis are limited. CT examination is radiative and requires iodine contrast medium with nephrotoxicity, which may require timely dialysis and long-term monitoring for hemodialysis patients. 3T MRI has no radiation and does not need to use iodine contrast agent, which can well detect parathyroid lesions . Previous studies have reported that 3T MRI can diagnose primary hyperparathyroidism (PHPT), but the diagnostic efficacy of SHPT is still unclear. Therefore, this study aims to evaluate the preoperative diagnostic value of non-enhanced 3T MRI compared with 4DCT in patients with secondary hyperparathyroidism after hemodialysis.

NCT ID: NCT05221008 Completed - Clinical trials for Secondary Hyperparathyroidism

A Trial of SHR6508 in Secondary Hyperparathyroidism

Start date: March 10, 2022
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the tolerability, pharmacokinetics and pharmacodynamics of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis

NCT ID: NCT04994080 Not yet recruiting - Clinical trials for Secondary Hyperparathyroidism

A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism

Start date: February 1, 2022
Phase: Phase 3
Study type: Interventional

The study is being conducted to evaluate the efficacy, and safety of Paricalcitol for secondary hyperparathyroidism with stage 3 and stage 4 chronic kidney disease in adults.

NCT ID: NCT04750460 Completed - Clinical trials for Secondary Hyperparathyroidism

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

TeriCa
Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.

NCT ID: NCT04484116 Completed - Clinical trials for Secondary Hyperparathyroidism

IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism

Start date: July 1, 2017
Phase:
Study type: Observational

Secondary hyperparathyroidism (SHPT) is a multisystemic syndrome that affects calcium and bone homeostasis in patients with chronic kidney disease (CKD). Despite medical treatment, 1-2% of patients require parathyroidectomy anually. The use of an intraoperative paratohormone protocol (IOPTH) to predict cure still in debate, due to the lack of standardized protocols, the use of different assays and uneven PTH clearance. The aim of this study was to determine the diagnostic accuracy of an IOPTH in patients with SHPT for predicting successful surgery after parathyroidectomy.

NCT ID: NCT03969329 Recruiting - Clinical trials for Secondary Hyperparathyroidism

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Start date: December 20, 2019
Phase: Phase 3
Study type: Interventional

Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric subjects between ≥ 2 to < 18 years of age, with chronic kidney disease (CKD) on hemodialysis

NCT ID: NCT03937349 Completed - Clinical trials for Secondary Hyperparathyroidism

Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients

Start date: May 14, 2019
Phase:
Study type: Observational

This is a prospective cohort study aimed to evaluate change of cardiovascular calcification after parathyroidectomy in patients with end-stage renal disease on dialysis compared with control group on conservative treatment.

NCT ID: NCT03822507 Completed - Clinical trials for Secondary Hyperparathyroidism

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Start date: April 9, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.

NCT ID: NCT03801980 Completed - Clinical trials for Secondary Hyperparathyroidism

Phase 3 Study of SK-1403

Start date: January 21, 2019
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of treatment with SK-1403 for 24 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.

NCT ID: NCT03660800 Completed - Clinical trials for Secondary Hyperparathyroidism

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Start date: August 20, 2018
Phase: Phase 1
Study type: Interventional

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and non-Japanese Healthy Subjects